Ken Griffin Tff Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.62 - $1.1 $27,597 - $48,963	-44,512 Reduced 96.66%	1,540 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.84 - $100.75 $6,898 - $827,459	-8,213 Reduced 15.13%	46,052 $48,000
Q3 2022 Nov 14, 2022	SELL	$4.61 - $116.0 $27,415 - $689,852	-5,947 Reduced 9.88%	54,265 $221,000
Q2 2022 Aug 15, 2022	BUY	$3.99 - $7.22 $26,589 - $48,114	6,664 Added 12.44%	60,212 $340,000
Q1 2022 May 16, 2022	SELL	$5.28 - $9.17 $348,939 - $606,017	-66,087 Reduced 55.24%	53,548 $338,000
Q4 2021 Feb 14, 2022	BUY	$6.86 - $9.65 $325,630 - $458,066	47,468 Added 65.78%	119,635 $1.06 Million
Q3 2021 Nov 15, 2021	SELL	$7.21 - $10.49 $135,951 - $197,799	-18,856 Reduced 20.72%	72,167 $557,000
Q2 2021 Aug 16, 2021	SELL	$8.48 - $13.61 $20,648 - $33,140	-2,435 Reduced 2.61%	91,023 $874,000
Q1 2021 May 17, 2021	BUY	$12.96 - $19.75 $754,272 - $1.15 Million	58,200 Added 165.07%	93,458 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$12.74 - $18.49 $463,264 - $672,351	-36,363 Reduced 50.77%	35,258 $505,000
Q3 2020 Nov 16, 2020	BUY	$5.86 - $18.47 $419,699 - $1.32 Million	71,621 New	71,621 $1.32 Million

Ticker TFFP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,477,800
Market Cap $1.53M
Description
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and condit...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.